



Atty. Dkt. No. 018792-0199

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Paul Averbach

Title: METHODS OF USING NEURAL THREAD PROTEINS TO TREAT TUMORS  
AND OTHER CONDITIONS REQUIRING THE REMOVAL OR DESTRUCTION  
OF CELLS

Appl. No.: 10/092,934

Filing Date: 03/08/2002

Examiner: Hong Sang

Art Unit: 1643

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR § 1.56**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR § 1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR § 1.97 and § 1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR § 1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR § 1.97(c), before the mailing date of either a final action under 37 CFR § 1.113, a notice of allowance under 37 CFR § 1.311, or an action that otherwise closes prosecution in the application.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP § 609.

**FEE**

A credit card payment form including the amount of \$180.00 is enclosed in accordance with 37 CFR § 1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR § 1.97(c) in the amount of \$180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date May 8, 2006

By Michele M. Simkin

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicant  
Registration No. 34,717



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: May 8, 2006

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/092,934
Filing Date	03/08/2002
First Named Inventor	Paul Averbach
Group Art Unit	1643
Examiner Name	Hong Sang
Attorney Docket Number	018792-0199

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C 1	SHIROTA, K., et al., "Characterization of Novel Kidney-Specific Delivery System Using an Alkylglucoside Vector," <i>J. Pharmacology and Experimental Therapeutics</i> , vol. 299, no. 2, 2001, pp. 459-467.	
	C 2	ZHOU, S, et al., "Delivery of glucocorticoid conjugate in rat gastrointestinal tract and its treatment for ulcerative colitis," <i>Acta Pharmacol Sin</i> , 2001 Aug, 22(8), pp. 761-764.	
	C 3	ANTCZAK, C., et al., "A new acivicin prodrug designed for tumor-targeted delivery," <i>NCBI, PubMed Abstract of Bioorg Med Chem</i> 2001 Nov, 9(11):2843-8.	
	C 4	BRADLEY, M., et al., "Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel," <i>Clinical Cancer Research</i> , vol. 7, October 2001, pp. 3229-3238.	
	C 5	DOWELL, J.A., et al., "Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse," <i>NCBI, PubMed Abstract of J. Clin Pharmacol</i> , 2001, Nov., 41(11):1206-14.	
	C 6	KRATZ, F., et al., "Drug-polymer conjugates containing acid-cleavable bonds," <i>NCBI, PubMed Abstract of Crit Rev Ther Drug Carrier Syst.</i> , 1999, 16(3):245-88.	
	C 7	OHYA, Y., et al., "Design of macromolecular prodrug of cisplatin using dextran with branched galactose units as targeting moieties to hepatoma cells," <i>NCBI, PubMed Abstract of Biomacromolecules</i> , 2001 Fall, 2(3), 927-33.	
	C 8	SAWA, T., et al., "Tumor-targeting Chemotherapy by a Xanthine Oxidase-Polymer Conjugate That Generates Oxygen-free Radicals in Tumor Tissue," <i>Cancer Research</i> 60, February 1, 2001, pp. 666-671.	
	C 9	SCHASCHKE, N., et al., "Beta-cyclodextrin/epoxysuccinyl peptide conjugates: a new drug targeting system for tumor cells," <i>NCBI, PubMed Abstract of Bioorg Med Chem Lett</i> . 2000 Apr. 3; 10(7), 677-80.	
	C 10	SHIAH, J., et al., "Antitumor Activity of N-(2-Hydroxypropyl)methacrylamide Copolymer-Mesochlorin e <sub>6</sub> and Adriamycin Conjugates in Combination Treatments," <i>Clinical Cancer Research</i> , vol. 6, March 2000, pp. 1008-1015.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.